February 17, 2023
February 17, 2023 - Travere Therapeutics, Inc. has announced that the U.S. Food and Drug Administration has granted accelerated approval to FilspariTM
- Have any questions?
- +1-888-INTL-SOS
- support@globalreachhealth.com
Global Reach Health News
February 17, 2023
February 17, 2023 – Apellis Pharmaceuticals, Inc. a global biopharmaceutical company and leader in complement, has announced that FDA has approved SyfovreTM
February 16, 2023
February 16, 2023 - Chiesi Global Rare Diseases, (a business unit of Chiesi Farmaceutici S.p.A., an
international research-focused healthcare Group, Chiesi Group)
February 3, 2023
February 3, 2023 - The Food and Drug Administration has approved sacituzumab govitecan-hziy
February 2, 2023
February 02, 2023 - FDA Industry News: From Our Perspective – CDER’s Continued Efforts to Widen Naloxone Access
By: Marta Sokolowska, Ph.D., CDER Deputy Center Director for Substance Use and Behavioral Health
By: Marta Sokolowska, Ph.D., CDER Deputy Center Director for Substance Use and Behavioral Health
February 2, 2023
February 2, 2023 Smiths Medical is recalling certain CADD Administration Sets and Medication Cassette Reservoirs, used with the CADD ambulatory
February 2, 2023
February 02, 2023 - Global Pharma Healthcare is voluntarily recalling all lots within expiry of their Artificial Tears Lubricant Eye Drops
February 1, 2023
February 1, 2023 - The FDA has recognized it needs to make its vaccination messaging simple and clear moving forward.
The COVID-19 pandemic has plagued America for nearly three years but the end might be in sight.